Yahoo · Oct 9, 2026
Could Gelteq’s (GELS) Gel Improve Oral Drug Delivery?
Gelteq has early company-reported data on a gel for oral drug delivery and a commercial product. Clinical proof and repeat customers are the next test.
NASDAQ · GELS
Healthcare · Drug Manufacturers - Specialty & Generic
$0.46
Down-$0.03 (-5.71%)
Updated Nov 5, 2026, 2:39 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · GELS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
GELS closed at $0.46 after 21 trading sessions, down 17.68% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $0.461 | $0.4892 | $0.45 | $0.4611 | 31.67K |
| Nov 3, 2026 | $0.45 | $0.4969 | $0.4433 | $0.489 | 47.36K |
| Nov 2, 2026 | $0.4687 | $0.4899 | $0.4617 | $0.4896 | 9.13K |
| Oct 30, 2026 | $0.481 | $0.498 | $0.45 | $0.4901 | 26.15K |
| Oct 29, 2026 | $0.5002 | $0.5352 | $0.48 | $0.506 | 77.21K |
| Oct 28, 2026 | $0.4749 | $0.49 | $0.4603 | $0.4814 | 14.22K |
| Oct 27, 2026 | $0.4442 | $0.4713 | $0.43 | $0.4583 | 29.04K |
| Oct 26, 2026 | $0.4785 | $0.495 | $0.4303 | $0.4473 | 823.34K |
| Oct 23, 2026 | $0.4363 | $0.4459 | $0.4303 | $0.4303 | 13.53K |
| Oct 22, 2026 | $0.4331 | $0.441 | $0.43 | $0.4349 | 25.06K |
| Oct 21, 2026 | $0.452 | $0.4559 | $0.4398 | $0.4398 | 10.26K |
| Oct 20, 2026 | $0.43 | $0.4515 | $0.43 | $0.448 | 23.97K |
| Oct 19, 2026 | $0.452 | $0.4649 | $0.43 | $0.4304 | 190.53K |
| Oct 16, 2026 | $0.44 | $0.49 | $0.431 | $0.446 | 40.23K |
| Oct 15, 2026 | $0.4461 | $0.4495 | $0.43 | $0.4306 | 18.71K |
| Oct 14, 2026 | $0.473 | $0.4783 | $0.45 | $0.4502 | 38.81K |
| Oct 13, 2026 | $0.49 | $0.5282 | $0.4801 | $0.4801 | 62.92K |
| Oct 12, 2026 | $0.4977 | $0.5164 | $0.4737 | $0.4902 | 52.85K |
| Oct 9, 2026 | $0.5595 | $0.5595 | $0.5212 | $0.5212 | 54.58K |
| Oct 8, 2026 | $0.5485 | $0.5525 | $0.54 | $0.5488 | 18.62K |
| Oct 7, 2026 | $0.5705 | $0.58 | $0.5501 | $0.5601 | 89.39K |
The latest Smart Investors Daily articles mentioning GELS.
Company
Market Activity
Research & News
GELS research
Company profile and research snapshot.
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 9, 2026
Gelteq has early company-reported data on a gel for oral drug delivery and a commercial product. Clinical proof and repeat customers are the next test.
ChartMill · Sep 22, 2026
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Benzinga · Sep 4, 2026
Gainers Immuron (NASDAQ:IMRN) stock increased by 64.9% to $1.83 during Friday's pre-market session. The company's market cap stands at $8.9 million. Akanda (NASDAQ:AKAN) shares increased by 27.52% to $4.68.
Benzinga · Sep 3, 2026
U.S. stocks climbed, led by Nasdaq; communications shares rose, energy fell, while MIMI surged and RARE plunged after trial failures.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning GELS.
No results
No recent SID articles mention GELS.